Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.

Rena Pollack,Itamar Raz,Stephen D Wiviott,Erica L Goodrich,Sabina A Murphy,Ilan Yanuv,Aliza Rozenberg,Ofri Mosenzon,Anna Maria Langkilde,Ingrid A M Gause-Nilsson,Deepak L Bhatt,Lawrence A Leiter,Darren K McGuire,John P H Wilding,Marc S Sabatine,Avivit Cahn

Diabetes care（2023）

引用 0|浏览49

暂无评分

摘要

The benefits and safety of dapagliflozin were maintained in high-risk patients receiving high-dose or intensive insulin regimens including SA insulin.

查看译文

关键词

dapagliflozin,baseline insulin regimen,declare-timi

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要